Ambeed.cn

首页 / / / / Ceftizoxime acid

头孢唑肟 /Ceftizoxime acid {[allProObj[0].p_purity_real_show]}

货号:A104202 同义名: Ceftizoxime

Ceftizoxime acid是一种第三代头孢菌素抗生素,具有强耐药性,对多种革兰阳性和革兰阴性微生物有效,广泛用于细菌性感染的治疗。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Ceftizoxime acid 化学结构 CAS号:68401-81-0
Ceftizoxime acid 化学结构
CAS号:68401-81-0
Ceftizoxime acid 3D分子结构
CAS号:68401-81-0
Ceftizoxime acid 化学结构 CAS号:68401-81-0
Ceftizoxime acid 3D分子结构 CAS号:68401-81-0
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Ceftizoxime acid 纯度/质量文件 产品仅供科研

货号:A104202 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Neuron, 2025. Ambeed. [ A1440350 ]
Nature Communications, 2025, 16, 996. Ambeed. [ A111960 , A505336 ]
JACS, 2025. Ambeed. [ A349578 , A2270125 ]
PLoS Biol., 2025, 23(2): e3002961. Ambeed. [ A181909 ]
Redox Rep., 2025, 30(1): 2454887. Ambeed. [ A1155014 ]
更多 >

Ceftizoxime acid 生物活性

描述 Ceftizoxime is a cephalosporin antibiotic. It works by interfering with the formation of the bacteria's cell wall so that the wall ruptures, resulting in the death of the bacteria.

Ceftizoxime acid 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03098485 Microbiota An... 展开 >>ti-bacterial Agents 收起 << Not Applicable Active, not recruiting June 30, 2019 United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 收起 <<
NCT00194532 Urinary Tract Infection Not Applicable Completed - United States, Florida ... 展开 >> University of Miami Miller School of Medicine Miami, Florida, United States, 33136 United States, Washington University of Washington Seattle, Washington, United States, 98195 收起 <<
NCT00194532 - Completed - -

Ceftizoxime acid 参考文献

[1]Nakajima F, Takaya K, et al. [Recombinant human granulocyte-colony stimulating factor (rhG-CSF) treatment for spleen abscess and periostitis in a patient with chronic granulomatous disease] . Rinsho Ketsueki. 1992 Dec;33(12):1869-74. Japanese.

[2]Frampton JE, Brogden RN, et al. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Nov;44(5):889-917.

Ceftizoxime acid 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.04mL

2.61mL

1.30mL

26.08mL

5.22mL

2.61mL

Ceftizoxime acid 技术信息

CAS号68401-81-0
分子式C13H13N5O5S2
分子量 383.403
别名 Ceftizoxime
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Inert atmosphere,Room temperature

溶解方案

DMSO: 25 mg/mL(65.21 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案一
方案二
动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。